Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

New infusible ECM hydrogel for treating acute myocardial infarction

Award Number: R43HL150917
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/20/2020
PERIOD OF PERFORMANCE END DATE: 04/30/2021

Group Awards By:

View Award Description

New infusible ECM hydrogel for treating acute myocardial infarction - Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a recurrent MI and a majority of these patients will suffer from heart failure. These staggering statistics necessitate the development of new therapies for patients with ischemic cardiomyopathy. Tissue engineering and regenerative medicine strategies offer significant potential for the development of novel therapies to treat these patients. Recently, acellular biomaterials have shown great promise in providing functional benefit without the complications associated with other regenerative medicine approaches. Injectable biomaterials that stimulate endogenous repair are an attractive alternative since potential therapies could still be delivered minimally invasively via catheter yet could be off the shelf and have significantly reduced costs compared to other regenerative medicine products, such as cells. Ventrix is therefore focusing on cell-free regenerative medicine approaches. Ventrix has a history of success in developing injectable biomaterials for treating ischemic cardiomyopathy. Two previous NIH SBIRs resulted in an approved IND for VentriGel, an injectable, catheter-deliverable hydrogel derived from decellularized porcine myocardium. This led to a recent successful Phase 1 clinical trial in patients 60 days to 3 years post-MI. The study proposed herein is a key step in bringing a new biomaterial product to market for treating acute MI. This new soluble version of VentriGel can be delivered via intracoronary infusion, which will enable treatment immediately post-MI, unlike the original formulation, which required transendocardial delivery. Herein, we will test the feasibility of translating this new technology by optimizing delivery and evaluating function in a large animal acute MI model. This will be the first intracoronary infusible regenerative biomaterial product for treating acute MI patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	VENTRIX INCORPORATED	3231 HILL ST	SAN DIEGO	CA	92106	SAN DIEGO	USA	Cardiovascular Diseases Research	000	1	11/16/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $791,543 )
2020	2020	VENTRIX INCORPORATED	3231 HILL ST	SAN DIEGO	CA	92106	SAN DIEGO	USA	Cardiovascular Diseases Research	000	1	5/20/2020	NEW	$791,543
														Subtotal = $791,543

Grand Total All Awards = $791,543

Top

All Categories

About

Search

Reports

Data Submission

Award Information

New infusible ECM hydrogel for treating acute myocardial infarction

Award Number: R43HL150917

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/20/2020

PERIOD OF PERFORMANCE END DATE: 04/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer